STOCK TITAN

Atrium Therapeutics: T. Rowe Price reports 3.7%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Atrium Therapeutics, Inc. (RNA) was the subject of an amended ownership report in which T. Rowe Price Associates, Inc. listed 640,034 common shares as beneficially owned as of September 30, 2026, equal to 3.7% of the class. It reported sole voting power over 639,822 shares and sole dispositive power over 640,034 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that the report is not an admission of beneficial ownership and expressly denied being the beneficial owner of the securities.

Reported beneficial ownership 640,034 shares T. Rowe Price Associates, Inc.; as of September 30, 2026; the reporting person expressly denied beneficial ownership.
Class ownership percentage 3.7% Reported by T. Rowe Price Associates, Inc. as of September 30, 2026.
Sole voting power 639,822 shares Reported by T. Rowe Price Associates, Inc. as of September 30, 2026.
Sole dispositive power 640,034 shares Reported by T. Rowe Price Associates, Inc. as of September 30, 2026.
beneficially owned regulatory
"Amount beneficially owned: 640034"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole voting power regulatory
"Sole voting power 639,822.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole dispositive power regulatory
"Sole dispositive power 640,034.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RNA shares did T. Rowe Price Associates report?

T. Rowe Price Associates, Inc. reported 640,034 Atrium Therapeutics common shares, or 3.7% of the class, as of September 30, 2026, while expressly denying beneficial ownership. It reported sole voting power over 639,822 shares and sole dispositive power over 640,034 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





04965N104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:11/16/2026

Keep reading